Actively Recruiting
"Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL
Led by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Updated on 2025-04-09
60
Participants Needed
3
Research Sites
323 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
It is a multicenter, non-interventional, non pharmacological, translational, prospective study. Any decision about drug administration is made by the physician based on his clinical judgment in the context of clinical practice, independently from the decision to include the patient in the study.
CONDITIONS
Official Title
"Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant is willing and able to give informed consent for participation in the study
- Patients with new diagnosis and/or relapse/s of primary or secondary B-ALL
- Negative for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements
- Male or Female, aged >18 years
- Availability of clinical data
You will not qualify if you...
- Age < 18 years
- B-ALL positive for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements
- Low blast percentage (<70%) samples may be excluded for molecular evaluations but not for cytofluorimetric analyses
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Irst Irccs
Meldola, FC, Italy, 47014
Actively Recruiting
2
Ospedale S. Maria delle Croci RAVENNA
Ravenna, RA, Italy, 48121
Actively Recruiting
3
Ospedale Infermi
Rimini, RN, Italy, 47923
Actively Recruiting
Research Team
O
Oriana Nanni, Dr
CONTACT
A
Anna Ferrari, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here